Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial

Abstract

Background Xingnaojing injection (XNJ) is widely used for the treatment of stroke in China. However, there is currently a lack of high-quality evidence of its efficacy for acute ischemic stroke. The main objective of this study is to determine whether the addition of XNJ to standard care improves the 3-month functional outcome in patients with acute ischemic stroke (AIS).Methods/designThe XMAS study is a multicenter, prospective, randomized controlled, open-label trial with a blinded endpoints design. A total of 720 patients will be randomly allocated to either the intervention or the control group in a 1:1 ratio. The intervention group receives XNJ combined with standard care, and the control group receives standard care alone. XNJ will be administered intravenously every 12 h for 10 days. The primary outcome is the proportion of patients who are independent at 3 months after stroke onset defined as a modified Rankin Scale score of 0 to 2. Secondary outcomes include early neurological deterioration at 48 h, the change in National Institutes of Health Stroke Scale score, patient-reported outcome, symptomatic intracranial hemorrhage at 10 days, the Barthel Index score, deaths from any cause and cardiovascular events at 3 months.DiscussionThe results of this trial will provide critical evidence for XNJ in the treatment of AIS as a complementary approach that can be initiated after reperfusion therapy or when the AIS is not eligible for thrombolytic treatment.Trial registrationClinical Trials.gov, ID: NCT02728180. Registered on 28 March 2016.Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-017-2222-y) contains supplementary material, which is available to authorized users.

Recent Advances in Chinese Herbal Medicine for Cerebral Ischemic Reperfusion Injury

“…The clinical study criteria should be documented to standardize the evaluation of CHM. Currently, except for Xingnaojing injection, Naoxuekang, Xinnaoshutong, and Xuesaitong capsules ( Chen et al, 2017 ; Lai et al, 2017 ), most CHM remedies used in the clinic have no ethics and dissemination registration number and trial registration number, and the trials did not follow the principles of randomization and blindness; besides this, the number of clinical samples was far from enough. These CHMs need reasonable and scientific clinical trials, and we call for more high-quality studies to confirm the neuroprotective effect and mechanism of CHM in others animal models such as dogs or rabbits in the future.…”

Efficacy and Safety of Xingnaojing Injection for Emergency Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

“…However, the unclear timing of XNJ initiation is still a prominent problem largely due to medical insurance restrictions and concerns around possible conflict between XNJ and IVT. Fortunately, some randomized, parallel-group, double-blind, multicenter trials are ongoing, such as a trial of the Tiantan hospital to evaluate efficacy and safety of XNJ for AIS patients with endovascular thrombectomy and a trial of the Dongzhimen hospital to investigate whether XNJ can be initiated after reperfusion therapy or when AIS is not eligible for IVT ( Lai et al, 2017 ).…”

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines

“…An ongoing clinical trial- Xingnaojing for moderate-to-severe acute ischemic stroke (Lai et al ) aimed to investigate whether Xingnaojing is able to improve outcomes of ischemic stroke patients at 3 months after stroke onset by running a multi-centred, prospective, randomized controlled, open label trial. The result is still pending ( Lai et al, 2017 ).…”